Source: Pharmacy Times articles
Despite the belantamab mafodotin regimen improving overall survival in patients with relapsed or refractory multiple myeloma, the trial is ongoing to confirm the presented results.
Read More
by | Mar 8, 2024 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Despite the belantamab mafodotin regimen improving overall survival in patients with relapsed or refractory multiple myeloma, the trial is ongoing to confirm the presented results.
Read More